[Development of the low molecular weight heparin fraction CY 216 in the prevention of postoperative thrombosis in general surgery].
Toulemonde
F
F
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006493:Heparin / Q000494:pharmacology / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D011183:Postoperative Complications / Q000517:prevention & control*; D013927:Thrombosis / Q000453:epidemiology / Q000517:prevention & control*
D006495:Heparin, Low-Molecular-Weight; D006493:Heparin
Développement de la fraction d'héparine de faible masse moléculaire CY 216 dans la prophylaxie des thromboses post-opératoires en chirurgie générale.